Category

• Pipeline2
• Research1

Organizations

• Bausch + Lomb64
• Eyes On Eyecare42
• Alcon, Inc.41
• American Optometric Association34
• Harrow26
• Glaukos25
• Regeneron21
• Aldeyra Therapeutics20
• Sight Sciences19
• American Academy Of Ophthalmology18

Tags

• Pediatrics3
• Eye Drops2
• Myopia2
• Aaopt1
• FDA1
• Atropine1
• Clinical Trials1
• New Drug Application1

• Organizations: Vyluma✕

Clear all

Pipeline

Positive 4-year data reported from phase 3 CHAMP study for pediatric myopia

Latest data on NVK002 builds on previous 3-year results released in May 2023.

Pipeline

FDA accepts Vyluma's NDA for NVK002 for pediatric myopia

A PDUFA target action date has been set for January 2024.

Research

Low-dose atropine shows benefits for pediatric myopia progression

New study supports the use of 0.01% atropine eye drops (NVK002).